Compare SPRY & BCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SPRY | BCX |
|---|---|---|
| Founded | 2015 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 987.3M |
| IPO Year | 2020 | N/A |
| Metric | SPRY | BCX |
|---|---|---|
| Price | $9.11 | $12.26 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $35.00 | N/A |
| AVG Volume (30 Days) | ★ 889.4K | 250.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 6.99% |
| EPS Growth | ★ 114.04 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $89,149,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $119.97 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 297063.34 | N/A |
| 52 Week Low | $6.66 | $7.84 |
| 52 Week High | $18.63 | $13.86 |
| Indicator | SPRY | BCX |
|---|---|---|
| Relative Strength Index (RSI) | 42.09 | 42.02 |
| Support Level | $8.61 | $11.86 |
| Resistance Level | $10.44 | $13.21 |
| Average True Range (ATR) | 0.44 | 0.32 |
| MACD | 0.03 | -0.13 |
| Stochastic Oscillator | 40.31 | 6.29 |
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.
BlackRock Resources & Commodities Strategy Trust operates as an investment trust. Its investment objective is to seek high current income and current gains, with a secondary objective of capital appreciation. The company invests at least 80% of its total assets in equity securities issued by commodity or natural resources companies, derivatives with exposure to commodity or natural resources companies or investments in securities and derivatives linked to the underlying price movement of commodities or natural resources.